BeiGene is next into MAT2A inhibition

After Ideaya validated MAT2A inhibition through promising clinical data for IDE397 others were bound to follow, and the next into this mechanism is BeiGene, which yesterday licensed global rights to CSPC Pharmaceutical's SYH2039. The precise deal terms are undisclosed, but include $150m in "up-front and time-based payments" plus milestones and royalties. A key feature is that BeiGene wants to combine SYH2039 with BGB-58067, an in-house PRMT5 inhibitor that it aims to put into the clinic this year. This mirrors one development path for Ideaya's IDE397, which is being combined with Amgen's PRMT5 inhibitor AMG 193. Notable recent MAT2A inhibitor entrants into phase 1 include Servier's S95035 and Insilico Medicine's ISM3412 – neither, so far, being combined with PRMT5 inhibitors. Meanwhile, other prominent PRMT5 inhibitors include Bristol Myers Squibb's Mirati-derived BMS-986504, Tango's TNG462 and AstraZeneca's AZD3470 – none in combination with MAT2A inhibitors. No clinical data are available on SYH2039, the molecule only having entered phase 1 in September. In July the first clinical data for IDE397 revealed a 39% ORR among 18 patients with MTAP-deleted solid tumours – an unpleasant surprise for GSK, which had turned down an option to license the project in 2022.

Clinical-stage MAT2A inhibitors

Notes: *formerly optioned to GSK as GSK4362676; **backup to the now discontinued Agios-originated AG-270/S095033. Source: OncologyPipeline.